Taiho Oncology and Cullinan Therapeutics reported positive Phase 3 data for zipalertinib plus chemotherapy in frontline lung cancer with EGFR exon 20 insertion mutations, with investigators halting the trial at an early data check due to clearly positive results. The companies said the combination met a pre-planned threshold for unblinding, setting up a regulatory decision pathway for the next-line setting. The story keeps pressure on the current standard-of-care ecosystem where EGFR exon 20 insertions have become an increasingly competitive niche. If zipalertinib is approved, it could join the growing list of targeted therapies used against Rybrevant-based regimens. The FDA is already reviewing zipalertinib as a second-line option, with a decision timeline expected to land by Feb. 27—creating a narrow window for companies to refine positioning based on how the first-line results translate to label scope.